Skip to main content
Retour
CSBTF logo

Kuros Biosciences AG

Qualité des données : 100%
Survendu
CSBTF
OTC Healthcare Biotechnology
29,00 €
▼ 0,49 € (-1,66%)
Cap. Boursière : 1,14B
Fourchette du Jour
29,00 € 29,50 €
Fourchette 52 Semaines
19,44 € 42,81 €
Volume
1 129
Moyenne 50J / 200J
33,36 € / 35,01 €
Clôture Précédente
29,49 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 536,1 0,3
P/B 17,0 2,9
ROE % 3,4 3,7
Net Margin % 1,8 3,8
Rev Growth 5Y % 72,2 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 0,00 €
0,00 € – 0,00 €
350 M 0
FY2029 0,00 €
0,00 € – 0,00 €
300 M 0
FY2028 1,21 €
1,11 € – 1,30 €
250 M 1

Points Clés

Revenue grew 72,16% annually over 5 years — strong growth
ROE of 3,37% is below average
Debt/Equity of 0,06 — conservative balance sheet
Negative free cash flow of -2,40M
P/E of 536,05 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 11,54%

Croissance

Revenue Growth (5Y)
72,16%
Revenue (1Y)60,62%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
3,37%
ROIC7,75%
Net Margin1,75%
Op. Margin6,04%

Sécurité

Debt / Equity
0,06
Current Ratio1,96
Interest Coverage24,04

Valorisation

P/E Ratio
536,05
P/B Ratio16,97
EV/EBITDA153,39
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 60,62% Revenue Growth (3Y) 90,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 72,16% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 121,36M Net Income (TTM) 2,12M
ROE 3,37% ROA 1,98%
Gross Margin 86,39% Operating Margin 6,04%
Net Margin 1,75% Free Cash Flow (TTM) -2,40M
ROIC 7,75% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,06 Current Ratio 1,96
Interest Coverage 24,04 Dividend Yield 0,00%
Valuation
P/E Ratio 536,05 P/B Ratio 16,97
P/S Ratio 9,36 PEG Ratio -3,55
EV/EBITDA 153,39 Dividend Yield 0,00%
Market Cap 1,14B Enterprise Value 1,12B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 121,36M 75,56M 33,56M 17,99M 13,82M
Net Income 2,12M -3,72M -13,73M -14,60M -7,54M
EPS (Diluted) 0,05 -0,10 -0,38 -0,43 -0,23
Gross Profit 104,84M 62,03M 28,47M 10,77M 10,07M
Operating Income 7,33M -5,00M -13,19M -13,45M -8,77M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 107,26M 84,54M 71,46M 82,95M 91,34M
Total Liabilities 40,30M 25,79M 14,75M 14,09M 14,36M
Shareholders' Equity 66,96M 58,75M 56,71M 68,86M 76,98M
Total Debt 3,94M 1,79M 2,14M 1,91M 2,15M
Cash & Equivalents 15,67M 17,46M 14,21M 24,07M 28,62M
Current Assets 65,52M 44,75M 27,19M 31,39M 32,89M
Current Liabilities 33,40M 20,90M 13,19M 12,59M 11,29M